RGX 381
Alternative Names: RGX-381Latest Information Update: 13 Nov 2023
At a glance
- Originator REGENXBIO
- Class Gene therapies; Neuroprotectants
- Mechanism of Action Gene transference; Tripeptidyl-peptidase 1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Neuronal ceroid lipofuscinosis
Most Recent Events
- 13 Nov 2023 RGX 381 is available for licensing as of 09 Nov 2023. https://www.regenxbio.com/who-we-are/
- 17 May 2023 Phase-I/II clinical trials in Neuronal ceroid lipofuscinosis (In children, In infants, Treatment-experienced) in United Kingdom (Intraocular) (NCT05791864)
- 31 Dec 2022 REGENXBIO has patent protection for RGX 381 in USA